Healthcare Industry News: HSMN NewsFeed
News Release - March 23, 2017
Tyme Appoints Ben Taylor as President and Chief Financial OfficerNEW YORK, March 23, 2017 -- (Healthcare Sales & Marketing Network) -- Tyme Technologies, Inc. (TYMI), (“Tyme” or “the Company”) a biotechnology company developing cancer therapeutics using metabolic pathways, today announced that Ben Taylor has been appointed President and Chief Financial Officer, effective April 3, 2017.
Mr. Taylor brings 18 years of life sciences experience in investment banking and emerging growth companies. He is joining Tyme from Barclays Capital Inc., where he has been the Head of Commercial Pharma since February 2016. Prior to Barclays, Mr. Taylor spent 10 years at Goldman, Sachs & Co. in various positions of increasing responsibility, most recently as Head of Emerging Pharma. Mr. Taylor has extensive experience in pharmaceutical business models, financing and strategic transactions, with a focus on developmental and midcap biopharma. In addition to investment banking, he also spent two years at a medical diagnostic start-up leading finance and business development functions.
“We are excited to have Ben join our executive team and to add his background and expertise working with biopharma companies as they transition into larger institutions,” said Steve Hoffman, CEO of Tyme. “Based on our interaction with Ben while he was with Barclays, we have seen his depth of industry knowledge as well as leadership capabilities, making him a great fit at Tyme.”
Tyme Technologies is developing a novel first-in-class therapy, SM-88, that is designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. SM-88 has demonstrated complete or partial responses in thirteen different cancer types due to the mechanism’s commonality across cancers. In addition, SM-88 therapy has not resulted in any drug-related serious adverse events during clinical testing or the expanded access programs. The Company is currently conducting a Phase II trial in prostate cancer as well as ongoing collaborations with the Mayo Clinic, Mount Sinai, the Albert Einstein College of Medicine and other institutions. For more information, visit our website: www.tymeinc.com.
Forward Looking Statements
This press release contains forward-looking statements. Readers can identify forward-looking statements by sentences or passages involving the use of terms such as “anticipates,” “believes,” “designed,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would,” and similar expressions intended to identify forward-looking statements. Forward-looking statements within this press release include, without limitation, statements regarding our drug development strategies, the therapeutic mechanisms of our drug candidates, the potential efficacy of SM-88 as a cancer treatment, and our completed and planned clinical trials. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned “Risk Factors” of Tyme’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2016 (available at www.sec.gov).
Forward-looking statements reflect Tyme’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. We are not necessarily obligated to update any forward-looking statement due to any change or development that occurs or may occur after the disclosure of such a statement. Given these uncertainties, readers should not place undue reliance on these forward-looking statements.
Source: Tyme Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.